-
Canadian Journal of Psychiatry. Revue... Apr 1991
Topics: Combined Modality Therapy; Delusions; Humans; Male; Middle Aged; Neurocognitive Disorders; Pimozide; Socioenvironmental Therapy
PubMed: 2059942
DOI: 10.1177/070674379103600328 -
The British Journal of Psychiatry : the... Mar 1982In a double blind trial, 28 male chronic schizophrenic in-patients received either pimozide, given once weekly, or fluphenazine decanoate, given mostly once fortnightly.... (Comparative Study)
Comparative Study
In a double blind trial, 28 male chronic schizophrenic in-patients received either pimozide, given once weekly, or fluphenazine decanoate, given mostly once fortnightly. There was no difference in relapse rates over nine months. However, three-quarters of the patients on pimozide who completed the trial developed at least mild tardive dyskinesia. All patients on pimozide lost weight, the average loss being 5.4 kg (12 lbs). Plasma pimozide levels suggested satisfactory drug compliance. Plasma prolactin levels confirmed that in the pimozide group there was fluctuating dopamine receptor antagonism, while in the fluphenazine group average plasma prolactin levels throughout most of the interval between injections were at the upper limit of normal.
Topics: Adult; Aged; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Male; Middle Aged; Pimozide; Prolactin; Schizophrenia
PubMed: 7093596
DOI: 10.1192/bjp.140.3.280 -
The British Journal of Psychiatry : the... Jul 1979
Topics: Delusions; Dyskinesia, Drug-Induced; Flupenthixol; Fluphenazine; Humans; Pimozide; Schizophrenia
PubMed: 497633
DOI: 10.1192/bjp.135.1.82 -
The Australian and New Zealand Journal... Mar 1985Eight severely retarded residents took part in a double blind, placebo controlled trial of pimozide. The drug did not alter behavioural adjustment as assessed by... (Clinical Trial)
Clinical Trial
Eight severely retarded residents took part in a double blind, placebo controlled trial of pimozide. The drug did not alter behavioural adjustment as assessed by behaviour observations. However, ratings on a standardised checklist of aberrant behaviour showed significant drug-induced improvements on two dimensions (Irritability and Hyperactivity/non-compliance). Learning performance, as assessed by a discrimination learning task, was not affected by the drug.
Topics: Adolescent; Clinical Trials as Topic; Discrimination Learning; Double-Blind Method; Female; Humans; Intellectual Disability; Male; Pimozide; Social Behavior Disorders
PubMed: 3890825
DOI: 10.3109/00048678509158820 -
Methods in Enzymology 1982
Topics: Administration, Oral; Cross Reactions; Humans; Kinetics; Male; Pimozide; Radioimmunoassay; Time Factors
PubMed: 7098966
DOI: 10.1016/0076-6879(82)84041-x -
Lancet (London, England) May 1977
Topics: Adolescent; Anorexia Nervosa; Humans; Male; Pimozide
PubMed: 68203
DOI: 10.1016/s0140-6736(77)92358-3 -
Pharmacology, Biochemistry, and Behavior Mar 2001Conditioned stimuli (CS) can be devalued by exposure to those stimuli in the absence of primary reward. We tested the hypothesis that dopamine (DA) mediates the control...
Conditioned stimuli (CS) can be devalued by exposure to those stimuli in the absence of primary reward. We tested the hypothesis that dopamine (DA) mediates the control of behavior by conditioned appetitive stimuli. Long-Evans rats were trained to respond for sucrose under a heterogeneous chain schedule in which seeking responses (lever press) turned on a houselight [variable interval (VI)-120 s]; taking responses (wheel turn or chain pull) in the presence of the houselight were reinforced [fixed ratio (FR)-1] by a sucrose pellet. When responding on this schedule was stable, the levers were retracted and subjects had access to the sucrose-taking manipulandum only. Sucrose-taking responses were either extinguished or reinforced under the influence of the DA antagonist, pimozide. Control groups were also reinforced for sucrose-taking responses but received no injection or a vehicle injection prior to each session. Responses of extinction and pimozide-treated groups declined over sessions. Sucrose-seeking responses were measured in a later test when subjects had no access to the sucrose-taking manipulandum or to the reinforcer. Both extinction and pimozide manipulations reduced seeking responses, relative to the respective control groups. Pimozide injections in the home cage had no effect. These data support the idea that DA mediates the conditioned reinforcing properties provided by access to the taking link of the chain.
Topics: Animals; Conditioning, Operant; Dopamine Antagonists; Feeding Behavior; Male; Pimozide; Rats; Rats, Long-Evans; Reinforcement, Psychology; Reward; Sucrose
PubMed: 11325415
DOI: 10.1016/s0091-3057(01)00460-9 -
Pharmacopsychiatria Mar 1982Thirty acutely hospitalized schizophrenic patients were treated under double blind condition with either haloperidol (40-60 mg/day) or pimozide (40-60 mg/day) for 30... (Clinical Trial)
Clinical Trial
Thirty acutely hospitalized schizophrenic patients were treated under double blind condition with either haloperidol (40-60 mg/day) or pimozide (40-60 mg/day) for 30 days. Ten patients in the pimozide and eleven in the haloperidol group showed a very good or good clinical response. There were no definite differences of treatment results as assessed by the Global Clinical Impression. Both groups showed a statistically significant decrease of the global scores of the Brief Psychiatric Rating Scale (p less than 0.01). There was a significant decrease of affective bluntedness and anergia in the pimozide but not in the haloperidol group. Extrapyramidal side effects were more pronounced in patients on pimozide who therefore needed more anticholinergic drugs. There was no consistent correlation between drug serum levels and global scores or single factors of the BPRS in either treatment group. It is concluded that pimozide in dose ranges from 40-60 mg has powerful antipsychotic properties indistinguishable from those of haloperidol but exerts stronger extrapyramidal side effects.
Topics: Acute Disease; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Pimozide; Schizophrenia
PubMed: 7043498
DOI: 10.1055/s-2007-1019512 -
Acta Psychiatrica Scandinavica Jul 1975An account is given of six cases treated with pimozide. Four of there cases fall into the diagnostic category of monosymptomatic hypochondriacal psychosis, a group with...
An account is given of six cases treated with pimozide. Four of there cases fall into the diagnostic category of monosymptomatic hypochondriacal psychosis, a group with a traditionally poor prognosis. Three out of the four have responded favourably to pimozide, while the fourth showed a partial improvement. A fifth case also showed a marked degree of improvement despite a possibility of early cerebral arteriopathy. The one case which showed no improvement was suspected all along of having a personality disorder rather than a psychotic illness, and this was subsequently confirmed. It is suggested that pimozide: a) may be an effective treatment for monosymptomatic hypochondriacal psychoses whatever their aetiology; and b) may differentiate rapidly between cases of monosymptomatic hypochondriacal psychoses and dysmorphophobias due to neurotically determined factors.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Hypochondriasis; Male; Middle Aged; Pimozide; Psychotic Disorders
PubMed: 1155199
DOI: 10.1111/j.1600-0447.1975.tb00019.x -
Pharmacology, Biochemistry, and Behavior Nov 1990Thirsty animals were trained to traverse a straight runway once each day for a reward consisting of 100 licks from a water-filled drinking tube. Once running speeds had...
Thirsty animals were trained to traverse a straight runway once each day for a reward consisting of 100 licks from a water-filled drinking tube. Once running speeds had stabilized, single daily extinction trials were initiated during which no water reinforcement was provided in the goal box. Extinction trials continued until running had slowed to levels approximately half of that observed during reinforced trials. A single treatment trial was then conducted in which some animals found water in the goal box and others continued to find an empty water bottle. Those subjects that were reinforced on treatment day subsequently demonstrated a reinstatement of their operant running response on the very next trial (i.e., 24 hr later). However, pretreatment with 1.0 mg/kg (but not 0.5 mg/kg) of the dopamine antagonist drug, pimozide, attenuated this response-reinstating effect of water-reinforcement. This action of pimozide was not likely a consequence of some residual sedative or motor incapacitation since a) the test day was conducted 24 hr after the treatment day by which time the pharmacological actions of the drug had greatly subsided; b) a Motor Control group administered pimozide after the reinforced trial exhibited normal response-reinstatement 24 hr later on Test Day; and c) on treatment day, pimozide did not reliably attenuate running times, latency to initiate drinking, nor the rate of licking behavior. Together, these data suggest that dopamine receptor antagonism can produce an attenuation in the reinforcing efficacy of water.
Topics: Animals; Conditioning, Operant; Extinction, Psychological; Male; Motor Activity; Pimozide; Rats; Rats, Inbred Strains; Reward; Water
PubMed: 2087488
DOI: 10.1016/0091-3057(90)90014-9